Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 10Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 12Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT01875653 2019-05-10

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Lisata Therapeutics, Inc.

Phase 3 Terminated
4 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡